Latest news with #MainzBiomed
Mint
21-05-2025
- Automotive
- Mint
Will AI empower the PR industry or create endless seas of spam?
Public-relations agencies email reporters every day with suggestions to cover their clients, but this pitch from March stood out from the flood with its unusual subject line: 'You care more about Tesla than a cancer killing thousands." The email went on to scold U.S.-based reporters for giving priority to Tesla earnings news and celebrity gossip over the work of Mainz Biomed, a German firm that develops tests for colorectal cancer. After rattling off statistics about increasing cancer rates, it stated, 'This isn't a future problem. It's happening right now. But you wouldn't know, because you've been covering crap that doesn't matter. Do better." This pitch was generated entirely by an artificial intelligence tool called PRAI, which suggested getting reporters' attention by combining the well-known Tesla name with a confrontational tone, according to Valentin Saitarli, who is chief executive of PRAI and managing director of Exclusive PR Solutions, a public relations firm that represents Mainz Biomed. It succeeded in generating attention—and hostility. 'This was an extremely efficient pitch and made lots of people angry, very angry," Saitarli said. 'We just wanted to showcase the product and invite to interviews, but we were attacked by so much hate." Mainz Biomed didn't respond to requests for comment. Is this the future of public relations? The email is an extreme example of AI being applied to PR without proper human oversight, according to communications veterans. But the field is already being changed by AI in other ways. Nearly every major PR firm has named an AI leader, and they have also developed a range of proprietary tools. Edelman, the largest global PR firm by revenue, has built a 'generative engine optimization" tool to improve clients' image among large language models as search results become less about driving clicks than maintaining reputations. When a client is the subject of negative headlines, the PR firm Golin can use AI to track more real-time responses and test potential responses on synthetic focus groups created by large language models, said Jeff Beringer, chief AI officer at the agency, part of Interpublic Group of Cos. The rise of generative AI has also facilitated a new wave of startups that automatically generate news releases and emails or cater to more niche PR functions. PodPitch was specifically designed to help communications professionals land their clients on podcasts, said co-founder Neal Shulman. Its product uses AI to match users' topical keywords with transcriptions from thousands of podcast episodes and generate personalized pitch emails based on clients' qualifications and the shows they are targeting, Shulman said. Big companies are also deploying AI for their own PR, communications and promotional activities. Microsoft last year developed a generative AI interface that summarizes mentions of Microsoft in news stories, podcasts and social-media posts so its communications team can more quickly develop a response strategy, said Steve Clayton, vice president of communications strategy at Microsoft. The company also uses its Copilot AI tool to develop social-media posts, conduct research and prepare executives for public speeches, but never releases any sort of AI-influenced content without thorough human review, according to Clayton. 'We're using it more as an input into the process than an output from the process," he said. When food delivery service Grubhub conducted research for a 2024 promotion that focused on meals for women who had just given birth, survey respondents rated sushi and shellfish as their biggest cravings. But when Grubhub used AI-powered facial recognition technology to scrutinize participants' expressions, they saw much greater enthusiasm for cold cuts and sandwiches. Grubhub subsequently edited the campaign's main video to include more comfort foods. 'You get a much better, more honest read on how they were feeling about that content versus what they say, because, you know, people are liars sometimes," said Dave Tovar, Grubhub's senior vice president of communications and government relations. AI has complicated the jobs of PR people as well. The technology made email outreach less effective by encouraging an ever-larger deluge of spam messages, according to Nick Toso, CEO and co-founder of Rolli, a tool that connects reporters with subject matter experts for their stories. It has also increased the prevalence of artificial 'experts" designed to trick journalists into quoting their commentary and boosting affiliated businesses' search engine rankings, said Toso, who was previously Washington, D.C., bureau chief and senior producer at CNN's Spanish-language division. Rolli uses AI tools and a team of human researchers to validate experts' identities and qualifications through extensive reviews of their articles, social-media posts and résumés, said Toso. 'If we're trying to tell people who the reliable sources are, we should also be able to tell them who the unreliable sources are," he said. PR shops can similarly vet influencers for clients more quickly by using AI to review years' of content, thereby ensuring that no past posts or comments could derail a brand's campaign. Some communications professionals remain skeptical that AI can encroach upon the discipline as quickly or as thoroughly as it has in the case of advertising. Communications relies more heavily on the nuances of one-on-one engagement between real humans, according to Wendy Zajack, adjunct faculty at Georgetown University's McDonough School of Business. Automation and AI-generated content risk getting in the way of that, according to Zajack, and bothering journalists to boot. 'I do feel like we might see an allergic reaction to some of this in terms of seeking out really interesting, individualistic content and messaging, because we have just been inundated with a lot of crap," she said. Write to Patrick Coffee at
Yahoo
20-05-2025
- Business
- Yahoo
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ('Mainz Biomed' or the 'Company'), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $2.00 per share and will expire five years from the date of issuance. Each Series B warrant will be immediately exercisable at an exercise price of $2.00 per share and will expire on the earlier of (i) 30 days following receipt of results from the Company's eAArly Detect 2 study, and (ii) one year from the date of issuance. Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about May 21, 2025, subject to customary closing conditions. The Company has also entered into a Warrant Amendment Agreement with the investor to reduce the effective strike price of both the Series A Warrants and Series B Warrants previously issued by the Company on December 12, 2024 (the 'December Series A Warrants' and the 'December Series B Warrant' respectively). Pursuant to the agreement, the strike prices of outstanding December Series A Warrants to purchase an aggregate of 1,367,521 of the Company's ordinary shares and the strike price of the December Series B warrants to purchase an aggregate of 1,367,521 of the Company's ordinary shares will be reduced to an amended exercise price of $2.00. The newly issued securities described above are being offered pursuant to a registration statement on Form F-1, as amended (File No. 333-287249) (the 'Registration Statement'), which was declared effective by the Securities and Exchange Commission (the 'SEC') on May 16, 2025. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Please visit Mainz Biomed's official website for investors at for more information About Mainz Biomed NVMainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit For media inquiries MC Services AGMaximilian Schur / Simone Neeten+49 211 529252 20mainzbiomed@ For investor inquiries, please contact info@ Forward-Looking StatementsCertain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'expect', 'estimate', 'plan', 'outlook', and 'project' and other similar expressions or the negative of such expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 'SEC') by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Associated Press
16-05-2025
- Business
- Associated Press
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ('Mainz Biomed' or the 'Company'), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test that integrates Mainz Biomeds proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test over a population of approximately 2,000 average-risk patients to validate the industry-leading results of previous feasibility studies and support the transition of CRC screening to CRC prevention. The eAArly DETECT 2 study is expected to complete enrollment in the second half of 2025, and the Company targets reporting top-line results by the fourth quarter of 2025. Based on the study's outcome, Mainz Biomed intends to finalize its protocols for ReconAAsense, the Company's U.S. pivotal study, which is on track to initiate in 2026. This next-generation CRC and APL (Adenomatous Polyps) test will not only detect cancerous polyps with a high degree of accuracy but can potentially prevent the disease through early detection of precancerous adenomas. 'We are excited about the progress the team has been making on eAArly DETECT 2 and look forward to providing partners and shareholders an interim update, targeted for the end of this summer,' commented Guido Baechler, Chief Executive Officer of Mainz Biomed. 'This clinical trial is particularly exciting for the Company, the patient community, and the medical professionals alike. By precisely detecting advanced precancerous lesions and early-stage CRC, we aim to advance our mission of eliminating colorectal cancer and ultimately reducing global cancer mortality rates.' The five novel gene expression (mRNA) biomarkers, which the Company acquired from Sherbrooke University in 2022, have demonstrated a unique ability to identify advanced adenomas – curable precancerous colonic polyps – as well as treatable early-stage CRC. The eAArly DETECT 2 study will further evaluate and confirm the effectiveness of these biomarkers combined with Mainz Biomed's proprietary algorithm to enhance product specifications, extending its capability to include the identification of advanced adenomas while increasing rates of diagnostic sensitivity and specificity for early-stage CRC. Please visit Mainz Biomed's official website for investors at for more information Please follow us to stay up to date: LinkedIn X (Previously Twitter) Facebook About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit or follow us on LinkedIn, Twitter and Facebook. For media inquiries MC Services AG Maximilian Schur / Simone Neeten +49 211 529252 20 [email protected] For investor inquiries, please contact [email protected] Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include information concerning possible or projected future results of our operations, including statements about our clinical trials and studies, business strategies or plans; prospects; future cash flows; financing plans; objectives of management; future cash needs; and any other statements that are not historical facts. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'expect', 'estimate', 'plan', 'outlook', and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 'SEC') by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Yahoo
16-05-2025
- Business
- Yahoo
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ('Mainz Biomed' or the 'Company'), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test that integrates Mainz Biomeds proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test over a population of approximately 2,000 average-risk patients to validate the industry-leading results of previous feasibility studies and support the transition of CRC screening to CRC prevention. The eAArly DETECT 2 study is expected to complete enrollment in the second half of 2025, and the Company targets reporting top-line results by the fourth quarter of 2025. Based on the study's outcome, Mainz Biomed intends to finalize its protocols for ReconAAsense, the Company's U.S. pivotal study, which is on track to initiate in 2026. This next-generation CRC and APL (Adenomatous Polyps) test will not only detect cancerous polyps with a high degree of accuracy but can potentially prevent the disease through early detection of precancerous adenomas. 'We are excited about the progress the team has been making on eAArly DETECT 2 and look forward to providing partners and shareholders an interim update, targeted for the end of this summer,' commented Guido Baechler, Chief Executive Officer of Mainz Biomed. 'This clinical trial is particularly exciting for the Company, the patient community, and the medical professionals alike. By precisely detecting advanced precancerous lesions and early-stage CRC, we aim to advance our mission of eliminating colorectal cancer and ultimately reducing global cancer mortality rates.' The five novel gene expression (mRNA) biomarkers, which the Company acquired from Sherbrooke University in 2022, have demonstrated a unique ability to identify advanced adenomas – curable precancerous colonic polyps – as well as treatable early-stage CRC. The eAArly DETECT 2 study will further evaluate and confirm the effectiveness of these biomarkers combined with Mainz Biomed's proprietary algorithm to enhance product specifications, extending its capability to include the identification of advanced adenomas while increasing rates of diagnostic sensitivity and specificity for early-stage CRC. Please visit Mainz Biomed's official website for investors at for more information Please follow us to stay up to date:LinkedInX (Previously Twitter)Facebook About Mainz Biomed NVMainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit or follow us on LinkedIn, Twitter and Facebook. For media inquiries MC Services AGMaximilian Schur / Simone Neeten+49 211 529252 20mainzbiomed@ For investor inquiries, please contact ir@ Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include information concerning possible or projected future results of our operations, including statements about our clinical trials and studies, business strategies or plans; prospects; future cash flows; financing plans; objectives of management; future cash needs; and any other statements that are not historical facts. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'expect', 'estimate', 'plan', 'outlook', and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 'SEC') by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Yahoo
29-04-2025
- Business
- Yahoo
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ('Mainz Biomed' or the 'Company'), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. 'We are delighted to join forces with EDX Medical Limited to improve access to high-quality cancer diagnostics in the UK,' said Guido Baechler, Chief Executive Officer of Mainz Biomed. 'By merging our expertise in molecular diagnostics with EDX Medical's excellent capabilities, we can provide a highly reliable and meaningful contribution to early cancer detection and prevention.' Dr Mike Hudson, CEO of EDX Medical, said: 'We are dedicated to making the very best diagnostic tests available to patients and healthcare professionals and are continuously looking to improve the performance of cancer testing by incorporating molecular biomarkers that can transform early cancer detection. We are delighted to form this technology partnership which will help us achieve this aim.' Please visit Mainz Biomed's official website for investors at for more information Please follow us to stay up to date:LinkedInX (Previously Twitter)Facebook About Mainz Biomed NVMainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit or follow us on LinkedIn, Twitter and Facebook. About EDX Medical Group EDX Medical Group plc is headquartered in Cambridge, UK, and is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally. For more information, please visit For media inquiries as to Mainz Biomed:MC Services AGMaximilian Schur / Simone Neeten+49 211 529252 20mainzbiomed@ For investor inquiries, please contact ir@ For media inquiries as to EDX Medical Group:Media House InternationalRamsay Smith+44 (0)7788 414856ramsay@ McQueen+44 (0)7834 694609gary@ Forward-Looking StatementsCertain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'expect', 'estimate', 'plan', 'outlook', and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 'SEC') by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
